公司資料
Milestone Pharmaceuticals Inc. 股價、新聞與催化劑
- 股票代碼:
- MIST
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Canada
股票表現
1.10 USD (0.00%)
收盤價
最後更新: 2026年8月17日
164M USD
市值
股價為何變動
As of Aug 17, 2026, MIST was little changed and closed at $1.10. No new same-company headline was identified in the current news window.
公司概覽
Self-Administered Cardiac Rescue Therapy
Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting.
CARDAMYST
CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal supraventricular tachycardia to sinus rhythm.
Atrial Fibrillation Expansion
The Phase 3 ReVeRA-301 study evaluates etripamil in atrial fibrillation with rapid ventricular rate. The program uses the same self-administered regimen approved for paroxysmal supraventricular tachycardia.
International Development
The European Medicines Agency is reviewing etripamil for paroxysmal supraventricular tachycardia under the proposed brand TACHYMIST.
未來催化劑
- Enrollment of the first patient in the Phase 3 ReVeRA-301 study of etripamil in atrial fibrillation with rapid ventricular rate.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。